NCT06335160 Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
| NCT ID | NCT06335160 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Ulcerative Colitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2024-04-20 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 46 participants in total. It began in 2024-04-20 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the possible efficacy and safety of mebendazole in patients with ulcerative colitis treated with mesalamine
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine) Exclusion Criteria: * \- Patients with severe UC * Significant liver and kidney function abnormalities * Diabetic patients * Patients with Colorectal cancer patients * Patients taking rectal or systemic steroids * Patients on immunosuppressants or biological therapies * Addiction to alcohol and / or drugs * Known allergy to the studied medications * History of complete or partial colectomy. * Patients with congestive heart failure, other heart disease (arrhythmia, ischemic heart disease including angina and myocardial infarction). * Patients with other inflammatory diseases and active infection. * Patients with stressful condition (COPD, morbid obesity). * Patients with liver disease. * Patients with thrombocytopenia and neutropenia. * Patients with any type of seizures (case report for mebendazole induced convulsion). * Patients with renal disease (case report for mebendazole induced nephrotoxicity). * Patients with coagulation disorders. * Patients on metronidazole (to avoid Stevens-Johnson syndrome). * Patients with hypersensitivity to mebendazole, albendazole or benzimidazole * Patients using antioxidants. * Pregnant and lactating females. * Patients receiving, metronidazole, warfarin, low dose of aspirin, clopidogril, enzyme inducers (phenytoin, carbamazepine) and inhibitors (valoproate) to avoid potential pharmacodynamics and pharmacokinetic interactions.
Frequently Asked Questions
Who can join the NCT06335160 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Ulcerative Colitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06335160 currently recruiting?
Yes, NCT06335160 is actively recruiting participants. Visit ClinicalTrials.gov or contact Tanta University to inquire about joining.
Where is the NCT06335160 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06335160 clinical trial?
NCT06335160 is sponsored by Tanta University. The trial plans to enroll 46 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.